Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA264620,10.7554/elife.85898,Elife,37772709,https://pubmed.ncbi.nlm.nih.gov/37772709,ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer,2023,"Human, Mitochondria, Drug resistance, Breast cancer, Stress response, Everolimus, Cancer Biology, Onc201/Tic10","Elena Farmaki, Aritro Nath, Rena Emond, Kimya L Karimi, Vince K Grolmusz, Patrick A Cosgrove, Andrea H Bild","The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lines, sensitive or resistant to everolimus, and discovered that combination treatment of ONC201/TIC10 (Read more on Pubmed)","Cell Culture, Western Blotting, RNA Sequencing","Breast Adenocarcinoma, Breast Carcinoma, Invasive Ductal Breast Carcinoma",Breast,"GSE119262,  GSE212369",Open Access,37772709,86632b66-24b4-448d-9a44-66b3d419f870,syn53129715
